Glucagon and GLP-1 receptor dual agonism : a therapeutic approach for the treatment of obesity
Obesity is a growing global epidemic and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs which aim to cause effective weight loss with minimal side effects. Two related peptide hormones, glucagon and glucagon-lik...
Main Author: | Cegla, Jaimini |
---|---|
Other Authors: | Bloom, Stephen |
Published: |
Imperial College London
2015
|
Subjects: | |
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739556 |
Similar Items
-
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
by: David S. Mathiesen, et al.
Published: (2019-08-01) -
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
by: David C. D. Hope, et al.
Published: (2021-09-01) -
Obesity alters global response to ischemia and GLP-1 agonism
by: Sassoon, Daniel Jay
Published: (2016) -
GLP-1R, a novel receptor in platelets, and the use of liraglutide in the treatment of obesity in women with PCOS
by: Kahal, Hassan
Published: (2013) -
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)